Press release
Hope on the Horizon: DelveInsight's AL Amyloidosis Clinical Trials Report Reveals Major Advancements in AL Amyloidosis Treatment | Alexion, Prothena Biosciences Ltd, Millennium Pharmaceuticals Inc, GlaxoSmithKline, Boston Medical Center, Janssen, and othe
AL Amyloidosis Pipeline
In the AL Amyloidosis Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, AL Amyloidosis NDA approvals (if any), and product development activities comprising the technology, AL Amyloidosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
To explore more information on the latest breakthroughs in the AL Amyloidosis pipeline treatment landscape of the report, click here @ AL Amyloidosis Pipeline- https://www.delveinsight.com/report-store/al-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the AL Amyloidosis Pipeline Report
• DelveInsight's AL Amyloidosis Pipeline analysis depicts a robust space with 10+ active players working to develop 10+ pipeline treatment therapies.
• The leading AL Amyloidosis Companies working in the market include Alexion, Prothena Biosciences Ltd, Millennium Pharmaceuticals Inc, GlaxoSmithKline, Boston Medical Center, Janssen Pharmaceuticals, Cephalon, Celgene Corporation, Prothena Biosciences Ltd, Genentech Inc, Sanofi, Bristol-Myers Squibb, Takeda, Sorrento Therapeutics Inc, Amgen, Criterium Inc, and others.
• Promising AL Amyloidosis Pipeline Therapies in the various stages of development include CAEL-101, SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD), Daratumumab, Ixazomib, Cyclophosphamide, Belantamab mafodotin, Pomalidomide, and others.
• On May 2023, Alexion announced a study of phase 3 clinical trials for CAEL-101. The primary purpose of this study is to determine whether CAEL-101, a monoclonal antibody that removes AL amyloid deposits from tissues and organs, improves overall survival and it is safe and well tolerated in patients with stage IIIa AL amyloidosis.
• On February 2023, Life Molecular Imaging GmbH announced a study of phase 3 clincial trials for [18F] florbetaben. This is an open-label, multi-center pivotal Phase 3 study to visually and quantitatively assess PET images obtained after single application of 300 MBq [18F] florbetaben and PET scanning of patients with suspected cardiac amyloidosis.
• On March 2023, European Myeloma Network announced a study of phase 2 clinical trials for Belantamab mafodotin. This is an open-label, multicenter, Phase 2 study in subjects with previously treated patients with light chain (AL) amyloidosis in need for therapy.
AL Amyloidosis Overview
AL amyloidosis is the most common type, with approximately 4,500 new cases diagnosed every year. It usually affects people from ages 50-80, although there are a few cases of people being diagnosed as early as their late 20s. About two-thirds of the patients are male.
To explore more information on the latest breakthroughs in the AL Amyloidosis Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/al-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
AL Amyloidosis Emerging Drugs Profile
• CAEL-101: Caelum Biosciences
• NXC-201: Nexcella, Inc.
AL Amyloidosis Pipeline Therapeutics Assessment
There are approx. 10+ key companies which are developing the therapies for AL Amyloidosis. The AL Amyloidosis companies which have their AL Amyloidosis drug candidates in the most advanced stage, i.e. phase III.
Request a sample and discover the recent advances in AL Amyloidosis Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/al-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
AL Amyloidosis Drugs and Companies
• CAEL-101: Alexion
• Dexamethasone: Millennium Pharmaceuticals Inc
• Belantamab Mafodotin: GlaxoSmithKline
• Daratumumab: Janssen Pharmaceuticals
• Pomalidomide: Boston Medical Center
AL Amyloidosis Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the AL Amyloidosis Therapeutics Market include-
Alexion, Prothena Biosciences Ltd, Millennium Pharmaceuticals Inc, GlaxoSmithKline, Boston Medical Center, Janssen Pharmaceuticals, Cephalon, Celgene Corporation, Prothena Biosciences Ltd, Genentech Inc, Sanofi, Bristol-Myers Squibb, Takeda, Sorrento Therapeutics Inc, Amgen, Criterium Inc, and others.
Dive deep into rich insights for drugs for AL Amyloidosis Pipeline, click here for AL Amyloidosis Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/al-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the AL Amyloidosis Pipeline Report
• Coverage- Global
• AL Amyloidosis Companies- Alexion, Prothena Biosciences Ltd, Millennium Pharmaceuticals Inc, GlaxoSmithKline, Boston Medical Center, Janssen Pharmaceuticals, Cephalon, Celgene Corporation, Prothena Biosciences Ltd, Genentech Inc, Sanofi, Bristol-Myers Squibb, Takeda, Sorrento Therapeutics Inc, Amgen, Criterium Inc, and others.
• AL Amyloidosis Pipeline Therapies- CAEL-101, SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD), Daratumumab, Ixazomib, Cyclophosphamide, Belantamab mafodotin, Pomalidomide, and others
• AL Amyloidosis Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on AL Amyloidosis Mergers and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/al-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. AL Amyloidosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. AL Amyloidosis- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. CAEL-101: Caelum Biosciences
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug Name: Company Name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. NXC-201: Nexcella, Inc.
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. LambdaMab 10B3 & 7F11: HaemaLogiX Ltd.
18. Drug profiles in the detailed report…..
19. Inactive Products
20. AL Amyloidosis Key Companies
21. AL Amyloidosis Key Products
22. AL Amyloidosis- Unmet Needs
23. AL Amyloidosis- Market Drivers and Barriers
24. AL Amyloidosis- Future Perspectives and Conclusion
25. AL Amyloidosis Analyst Views
26. AL Amyloidosis Key Companies
27. Appendix
List of Top Selling Market Research Reports in 2023
https://www.delveinsight.com/report-store/alcoholic-hepatitis-market
https://www.delveinsight.com/report-store/b-cell-maturation-antigen-targeted-therapies-market
https://www.delveinsight.com/report-store/blastomycosis-market
https://www.delveinsight.com/report-store/chronic-pulmonary-infections-due-to-pseudomonas-aeruginosa-in-patients-with-cystic-fibrosis-market
https://www.delveinsight.com/report-store/c-x-c-chemokine-receptor-inhibitors-competitive-landscape-market-and-pipeline-analysis
https://www.delveinsight.com/report-store/digestive-system-fistula-market
https://www.delveinsight.com/report-store/fertility-monitoring-devices-fertility-testing-devices-market
https://www.delveinsight.com/report-store/hay-fever-conjunctivitis-market
https://www.delveinsight.com/report-store/kawasaki-disease-market
https://www.delveinsight.com/report-store/myopia-progression-market
https://www.delveinsight.com/report-store/pecoma-market
https://www.delveinsight.com/report-store/pediatric-growth-hormone-deficiency-market
https://www.delveinsight.com/report-store/percutaneous-arterial-closure-device-market
https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
https://www.delveinsight.com/report-store/upper-tract-urothelial-cancer-market
https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
https://www.delveinsight.com/report-store/uk-healthcare-outlook-report
https://www.delveinsight.com/report-store/supraventricular-tachycardia-market
https://www.delveinsight.com/report-store/stem-cell-market
https://www.delveinsight.com/report-store/soft-tissue-defect-market
https://www.delveinsight.com/report-store/small-lymphocytic-lymphoma-market
https://www.delveinsight.com/report-store/shigella-infections-market
https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
https://www.delveinsight.com/report-store/radiation-retinopathy-market
https://www.delveinsight.com/report-store/primary-biliary-cholongitis-pbc-market
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hope on the Horizon: DelveInsight's AL Amyloidosis Clinical Trials Report Reveals Major Advancements in AL Amyloidosis Treatment | Alexion, Prothena Biosciences Ltd, Millennium Pharmaceuticals Inc, GlaxoSmithKline, Boston Medical Center, Janssen, and othe here
News-ID: 3142681 • Views: …
More Releases from DelveInsight Business Research
Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Compani …
DelveInsight's, "Niemann Pick C Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type C pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type C pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this…
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, D …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast
https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, D …
The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the Osteogenesis Imperfecta market dynamics.
DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteogenesis Imperfecta, historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market trends in the United…
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,…
More Releases for Amyloidosis
Amyloidosis Market Massive Growth opportunity Ahead
Introduction
Amyloidosis is a rare, progressive disease characterized by the abnormal deposition of amyloid proteins in tissues and organs, leading to organ dysfunction and, in severe cases, life-threatening complications. The condition can affect the kidneys, heart, liver, and nervous system, making early detection and effective treatment essential. Historically underdiagnosed, amyloidosis is now gaining visibility due to advances in diagnostic tools, imaging technologies, and therapeutic innovations.
In 2024, the global Amyloidosis Market is…
Evolving Market Trends In The Transthyretin Amyloidosis Treatment Industry: Inno …
The Transthyretin Amyloidosis Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Transthyretin Amyloidosis Treatment Market Size During the Forecast Period?
The market for transthyretin amyloidosis treatments has witnessed significant growth in the past few years. The market, which was valued at…
What's Driving the Transthyretin Amyloidosis Treatment Market 2025-2034: Increas …
What Are the Projections for the Size and Growth Rate of the Transthyretin Amyloidosis Treatment Market?
The market for transthyretin amyloidosis treatment has seen robust growth in the past years. Its size is forecasted to increase from $5.52 billion in 2024 to $5.95 billion in 2025, with a compound annual growth rate (CAGR) of 7.8%. The surge in the market over the historic period is due to increased disease awareness, progress…
Unveiling Transthyretin Amyloidosis Treatment Market 2024
The transthyretin amyloidosis treatment market size has grown strongly in recent years. It will grow from $5.07 billion in 2023 to $5.52 billion in 2024 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to increased disease awareness, advancements in diagnostic tools, drug development and approvals, patient advocacy and support, collaboration in research..
The transthyretin amyloidosis treatment market size is…
AL Amyloidosis Therapeutics Market - Transforming the landscape of AL amyloidosi …
Newark, New Castle, USA: The "AL Amyloidosis Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
AL Amyloidosis Therapeutics Market: https://www.growthplusreports.com/report/al-amyloidosis-therapeutics-market/8684
This latest report researches the industry structure,…
Transthyretin Amyloidosis (ATTR) Market 2022 | Detailed Report
The top-notch information research report published by markets and markets is a vital asset that offers qualitative and quantitative factors of the Transthyretin Amyloidosis (ATTR) market. The research study and methodologies mentioned in the report examine the critical vendors by considering their contribution to the global market. Furthermore, the report offers an in-depth insight into leading players’ performance based on revenue generation and client requirements. Also, the research report reveals…
